Background Image
Previous Page  138 / 156 Next Page
Information
Show Menu
Previous Page 138 / 156 Next Page
Page Background

136

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

154

KAMPEN W.-U, FISCHER M. Einsatz offener Radionuklide in der Schmerztherapie. Der

Schmerz 2008. Springer Verlag; 22 (6): 699-706.

155

Keskinbora K, Pekel AF, Aydinli I. Gabapentin and an opioid combination versus opioid

alone for the management of neuropathic cancer pain: a randomized open trial. J Pain

Symptom Manage 2007; 34(2): 183-189.

156

Kim DY, Song HS, Ahn JS, Ryoo BY, Shin DB, Yim CY, Kim SY. The dosing frequency of susta-

ined-release opioids and the prevalence of end-of-dose failure in cancer pain control: a

Korean multicenter study. Support Care Cancer 2010; 19(2): 297-301.

157

Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, Davies A, Kloke M,

Lundström S, Maltoni M, Radbruch L, Sabatowski R, Sigurdardottir V, Strasser F, Fayers

PM, Kaasa S. Influence from genetic variability on opioid use for cancer pain: a European

genetic association study of 2294 cancer pain patients. Pain 2011; 152(5): 1139-1145.

158

Knudsen AK, Brunelli C, Kaasa S, Apolone G, Corli O, Montanari M, Fainsinger R, Aass

N, Fayers P, Caraceni A, Klepstad P; European Palliative Care Research Collaborative;

European Pharmacogenetic Study. Which variables are associated with pain intensity and

treatment response in advanced cancer patients? Implications for a future classification

system for cancer pain. Eur J Pain 2011; 15(3): 320-327.

159

Kollender Y, Bickels J, Stocki D, Maruoani N, Chazan S, Nirkin A, Meller I, Weinbroum AA.

Subanaesthetic ketamine spares postoperative morphine and controls pain better than

standard morphine does alone in orthopaedic-oncological patients. Eur J Cancer 2008;

44(7): 954-962.

160

Kömürcü S, Turhal S, Altundağ K, Atahan L, Turna HS, Manavoğlu O, Yavuz AA, Ozkök S,

Aliustaoğlu M, Altinbaş M, Pak Y, Cooper R, Yaylaci M, Demirkan B, Sarihan S, Ozdemir F.

Safety and efficacy of transdermal fentanyl in patients with cancer pain: Phase IV, Turkish

oncology group trial. Eur J Cancer Care (Engl.) 2007; 16(1): 67-73.

161

Kotb HI, Fouad IA, Fares KM, Mostafa MG, Abd El-Rahman AM. Pharmacokinetics of oral

tramadol in patients with liver cancer. J Opioid Manag 2008; 4(2): 99-104.

162

Krajnik M, Podolec Z, Siekierka M, Sykutera M, Pufal E, Sobanski P, Makarewicz R, Neef C,

Punt N, Zylicz ZMorphine inhalation by cancer patients: a comparison of different nebuli-

zation techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain

Symptom Manage 2009; 38(5): 747-757.

163

Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of

intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer:

a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial

with a 10-month, open-label extension treatment period. Clin Ther 2009; 31(6): 1177-

1191.

164

Kress HG, Von der Laage D, Hoerauf KH, Nolte T, Heiskanen T, Petersen R, Lundorff L,

Sabatowski R, Krenn H, Rosland JH, Saedder EA, Jensen NH. A randomized, open, parallel

group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal

fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom

Manage 2008; 36(3): 268-279.

165

Kretzschmar A, Wiegel T, Al-Batran S-E, Hinrichs HF, Kindler M, Steck T,

Literaturverzeichnis